Dual antiplatelets and cardiac stents - time for a re-think?

This novel study from the NEJM investigates the outcome of dual antiplatelet therapy and in-stent thrombosis

Traditional guidelines have suggested that dual antiplatelets should continue for 12 months when a cardiac drug eluting stent has been placed. This New England Journal of Medicine study evaluates the outcomes of nearly 10,000 patients with drug eluting stents in situ. The study suggests a lowered rate of in-stent thrombosis if dual antiplatelets are continued after 12 months.

Time for a re-think about timing of antiplatelet therapy?

NEJM - Click here for a link to the article

Leave your comments

Post comment as a guest

Your comments are subjected to administrator's moderation.
terms and condition.
  • No comments found

Who's Online

We have 6 guests and no members online